Physician profile
Sarah M Devine
NPI 1639286016
$3,740.13
in general payments reported to CMS, 2019-2025
42 companies · $786 in 2025
The $786 reported for 2025 was more than what 81% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $554 · 2020: $342 · 2021: $696 · 2022: $657 · 2023: $318 · 2024: $387 · 2025: $786.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,491.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,490.93 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $397.12 | 2019-2024 | Evenity, Prolia |
| Novo Nordisk INC | $377.10 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Lilly USA, LLC | $369.99 | 2019-2025 | Mounjaro, Zepbound, Jardiance |
| Novartis Pharmaceuticals Corporation | $334.30 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $323.36 | 2021-2025 | |
| Astrazeneca Pharmaceuticals Lp | $278.47 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Janssen Pharmaceuticals, INC | $177.57 | 2019-2022 | |
| Pfizer INC. | $174.66 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $132.52 | 2019-2024 | Xifaxan |
| Takeda Pharmaceuticals U.S.A., INC. | $110.67 | 2019-2025 | Trintellix |
| Biohaven Pharmaceuticals, INC. | $89.09 | 2021 | |
| Genentech USA, INC. | $87.18 | 2019-2020 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $76.77 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $69.37 | 2021-2025 | Gardasil 9, Capvaxive |
| Astellas Pharma US INC | $68.12 | 2019-2021 |
Show all 42 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sarah Devine listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.